title: Delay and restricted access of new molecules in Turkey compared to the United States and European Union.
abstract: OBJECTIVE
  This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013.
  
  
  METHODS
  The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketing authorization approval after January 1, 2007, in the European Union. The launch dates for the European Union, the United States, and Turkey were retrieved from the same database. Data for Turkey were confirmed via IMS and RxMedia.
  
  
  RESULTS
  Out of 183 records identified that are launched in the European Union, the United States, or both, 44 of the NMs are launched in Turkey (24%).
  
  
  CONCLUSIONS
  The results of this study show that 24% of the NMs that are launched in either the European Union or United States were able to be launched in Turkey with a mean delay of 821 days (2.25 years).
authors.affiliation: Sanofi Turkey, Market Access, Istanbul, Turkey.
authors.forename: Toros
authors.initials: T
authors.lastname: Şahin
authors.affiliation: Sanofi Turkey, Market Access, Istanbul, Turkey.
authors.forename: Atakan
authors.initials: A
authors.lastname: Yeşil
authors.affiliation: Sanofi Turkey, Market Access, Istanbul, Turkey.
authors.forename: Türker
authors.initials: T
authors.lastname: Topcu
keywords: Turkish pharmaceutical market; access to medicine; launch; new molecules